<DOC>
	<DOCNO>NCT02280070</DOCNO>
	<brief_summary>To evaluate efficacy safety SOX mFOLFOX6 neoadjuvant chemotherapy patient resectable rectal cancer , identify promise regimen .</brief_summary>
	<brief_title>RP II Study SOX v mFOLFOX6 Patients With Resectable Rectal Cancer ( KSCC1301 ) .</brief_title>
	<detailed_description>1 . Patient registration procedure If confirm subject meet inclusion criterion correspondent none exclusion criterion , subject register use CReS Kyushu registration/allocation system ( CK-RAS ) . The registration CK-RAS available 24hr ( URL : http : //reg.cres-kyushu.or.jp/qmin/login/ ) need individual ID password . 2 . Quality management 1 . Monitoring A central monitoring in-site monitoring carry base data case report form ( CRF ) collect data coordinate center . In principle , on-site monitoring carry , may carry on-site monitoring determine need Kyushu Study group Clinical Cancer ( KSCC ) steer committee result central monitoring . 2 . Data Monitoring Committee A Data Monitoring Committee ( DMC ) establish . 3 . Data entry All data enter double entry method . Referential data rule , valid value , range check , consistency check data already store database support . Checks apply time data entry specific field . Additional error detect program design detect miss data specific error data . The investigator receive inquiry respond check original form inconsistency , check source determine correction , modify original paper form enter response query . 4 . Regular monitoring report A regular monitoring report generate data coordinate center submit KSCC Steering Committee , principal investigator , DMC etc review accord `` KSCC regulation monitoring '' . The information status site EC approval achievement enrollment : number enrollment- total/per periodical , total/per site , report monthly use e-mail . - Contents monitor report 1 . Study abstract : schema/purpose/subject/endpoint/definition treatment/anticipated enrollment number/progress study 2 . Enrollment status : per participate site/total 3 . Monitoring activity : content activity/CRF collection per site/uncollected CRF , inquiry 4. Review eligible treatment caseï¼šthe case ineligible possibility/the case determine ineligible/number eligible case/the case determine non-treatment/total number treatment case 5. Review target population analysis : number case target efficacy analysis/safety analysis 6 . Patient background 7 . Treatment time-course : summary on-treatment discontinuation/summary reason discontinuation/list reason discontinuation 8 . Protocol violation/deviation 9 . Safety evaluation : serious adverse reaction , event/the case notify study group among adverse reaction , event ordinary report/general adverse event 10 . Others 5 . Audit A site audit carry audit member KSCC Coordinating Center , data coordinate center , medical staff site approval site director accord `` KSCC regulation site audit '' . The result audit report site director , KSCC Steering Committee , principal investigator etc . ( require , DMC ) .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Hepatitis C Antibodies</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Written inform consent Patients judge suitable receive protocol therapy physician Distal border tumor locate peritoneal reflection Histologically confirm rectal adenocarcinoma Previously untreated rectal cancer Within 28 day registration , tumor consider surgeon amenable curative resection [ T category : cSS cSE , cSI , cA , cAI . N category : cN02 cN3 ( # 253 lymph node ) ] Within 28 day registration , evidence distant metastasis contrastenhanced CT &gt; = 20 year old PS ( ECOG ) 01 Be able take oral drug Required baseline laboratory parameter ( within 14 day registration ) : WBC &gt; = 3000 , &lt; 12000/mm3 , Neu &gt; = 1,500/ mm3 , Hb &gt; = 9.0g/dl , Plt &gt; = 100,000/ mm3 , TBil &lt; = 2.0mg/dl , AST , ALT &lt; = 100U/L , Cre &lt; 1.5mg/dl , Ccr &gt; = 60mL/min Considered survive 3 month History serious drug hypersensitivity history drug allergy Pregnant lactate woman man hope Partner 's pregnant Active infection ( 38 degree ) Serious complication ( ex . interstitial pneumonitis , pulmonary fibrosis , renal failure , liver failure , serious diabetes , serious hypertension ) Clinically significant abnormal electrocardiogram heart disease Serious diarrhea Pleural effusion , peritoneal fluid need treatment Previous history serious lung disorder ( ex . interstitial lung disease fibrosis , serious emphysema ) Hemorrhagic diathesis , coagulation disorder Active double cancer ( synchronous double cancer asynchronous double cancer diseasefree duration 5 year less ) Patients need flucytosine , phenytoin warfarin potassium Requiring steroid drug Patients contraindication therapy History allergy contrast material Serious stricture ( exclude patient put stoma ) Positive HBs antigen HCV antibody Not appropriate study physician 's assessment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>resectable rectal cancer</keyword>
	<keyword>SOX</keyword>
	<keyword>mFOLFOX6</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>